FDA Places Import Alert on Products from Two Ranbaxy Plants

U.S. FDA says it has issued an import alert for officials to detain drugs reaching the U.S. border that have been made at two Indian plants owned by pharmaceutical manufacturer Ranbaxy Laboratories (Gurgaon, India). FDA says it has issued two warning letters to Ranbaxy relating to the company’s generic pharmaceutical production plants at Dewas and Paonta Sahib, India for deviating from U.S. good manufacturing practice (GMP) .  FDA says it has taken the severe action to detain product made at the plants “because of the extent and...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers